| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
564,050,000 |
| Market
Cap: |
54.09(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0959 - $0.0959 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Zomedica is a biopharmaceutical company targeting health and wellness solutions for the companion pet. Co.'s primary drug product candidate is ZM-007, an oral suspension formulation of metronidazole, targeting the treatment of acute diarrhea in small dog breeds and puppies under nine pounds or four kilograms. Co.'s second drug product candidate is ZM-012, a tablet formulation of metronidazole and a complementary formulation to ZM-007, targeting the treatment of acute diarrhea in dogs. Co.'s third drug product candidate is ZM-006, a transdermal gel formulation of methimazole targeting the chronic treatment of hyperthyroidism in cats.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,550,000 |
1,550,000 |
2,100,000 |
2,300,000 |
| Total Buy Value |
$233,599 |
$233,599 |
$325,749 |
$364,179 |
| Total People Bought |
5 |
5 |
5 |
5 |
| Total Buy Transactions |
10 |
10 |
15 |
17 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Williams Rodney James |
Director |
– • – |
2018-03-23 |
4 |
OE |
$0.20 |
$28,000 |
D/D |
140,000 |
140,000 |
|
- |
|
| Rowe Jeffrey M |
Director |
– • – |
2018-03-23 |
4 |
OE |
$0.20 |
$20,000 |
D/D |
100,000 |
100,000 |
|
- |
|
| Shameze Rampertab |
Chief Financial Officer |
• • – |
2018-03-12 |
4 |
OE |
$0.20 |
$35,200 |
D/D |
176,000 |
340,000 |
|
- |
|
| Lebar James |
Director |
– • – |
2018-01-24 |
4 |
OE |
$0.20 |
$20,000 |
D/D |
100,000 |
220,000 |
|
- |
|
| Shameze Rampertab |
Chief Financial Officer |
• • – |
2018-01-08 |
4 |
OE |
$0.20 |
$24,800 |
D/D |
124,000 |
164,000 |
|
- |
|
| Solensky Gerald Jr |
President and CEO |
• • • |
2017-12-19 |
4 |
OE |
$1.20 |
$900,000 |
D/D |
750,000 |
37,951,100 |
|
- |
|
56 Records found
|
|
Page 3 of 3 |
|
|
